Novel methods of antiepileptic drug delivery — Polymer-based implants

Halliday, Amy J.; Moulton, Simon E.; Wallace, Gordon G.; Cook, Mark

doi:10.1016/j.addr.2012.04.004

Cited by 55 publications

(41 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After the acid is neutralized by gland secretions of pancreatic, biliary and Brunner’s in duodenum, the pH value can turn into 4.8–8.2 and then become stable ranging from 7.0 to 7.5 in colon [3, 28, 29]. Recently, electrospun nanofibers show great potential as implantable drug carriers and functional coating of medical devices for local drug delivery [30, 31]. Use of electrospun nanofibers for pH-responsive drug delivery to particular targets could be an intriguing approach.…”

Section: Discussionmentioning

confidence: 99%

Mussel-inspired protein-mediated surface functionalization of electrospun nanofibers for pH-responsive drug delivery

et al. 2014

View full text Add to dashboard Cite

pH-responsive drug delivery systems could mediate drug releasing rate by changing pH values at specific time as per the pathophysiological need of the disease. Herein, we demonstrated a mussel inspired protein polydopamine coating can tune the loading and releasing rate of charged molecules from electrospun poly (ε-caprolactone) (PCL) nanofibers in solutions with different pH values. In vitro release profiles showed that the positive charged molecules released significantly faster in acidic than those in neutral and basic environments within the same incubation time. The results of fluorescein diacetate staining and 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays showed the viability of cancer cells after treatment with doxorubicin released media at different pH values qualitatively and quantitatively, indicating the media contained doxorubicin which was released in solutions at low pH values could kill significantly higher number of cells than that released in solutions at high pH values. Together, the pH-responsive drug delivery systems based on polydopamine-coated PCL nanofibers could have potential applications in oral delivery of anticancer drugs for treating gastric cancer and vaginal delivery of anti-viral drugs or anti-inflammatory drugs, which could raise their efficacy, deliver them to the specific target, and minimize their toxic side effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Mussel-inspired protein-mediated surface functionalization of electrospun nanofibers for pH-responsive drug delivery

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The benefits are similar to microsphere placement but the amount of drug can be higher. In addition, the polymer can be degraded with no residue, toxin, or foreign substance remaining in the subject [52]. The drawbacks include size, which could limit where it can be placed, and diffusion.…”

Section: Going Around the Blood-brain Barriermentioning

confidence: 99%

Barriers to Drug Delivery for Brain Trauma

Willyerd

Empey

Kochanek

et al. 2013

Vascular Mechanisms in CNS Trauma

View full text Add to dashboard Cite

One of the most opposing barriers-both literally and figurativelychallenging the translational advancement of therapeutics targeting brain trauma involves effective delivery of potentially neuroprotective agents to the damaged brain. Aspects distinguishing delivery of drugs to the injured brain relative to other tissues include: (1) several unique physical features of the blood-brain barrier (BBB) vs. other blood-tissue barriers; (2) added diffusion distance associated with astrocyte swelling (in addition to interstitial edema) away from the therapeutic target; and (3) membrane transporters at both the BBB and blood-CSF barriers (BCSFB), such as ATP-binding cassette (ABC) transporters, organic anion transporters (OAT), and organic anion transporting peptides (OATP) that have the capacity to move drug substrates out of the brain, actively reducing brain bioavailability. While these "barriers" represent unique challenges to the development of efficacious neuroprotective agents for the treatment of traumatic brain injury (TBI), recent pharmacological advancements provide an optimistic outlook for designing strategies that impact outcome for victims of TBI in the near future.

show abstract

“…Importantly, the side effects of those drugs prevent large increase in the dose [8]. Alternative therapies aimed at improving the availability of AEDs such as the intracranial implantation of polymer-based drug delivery systems are being investigated [9,10]. This targeted drug delivery approach has been shown to be useful in the treatment of animal models of several neurological disorders such as Parkinson's disease, Huntington's disease and Alzheimer's disease [11].…”

Section: Introductionmentioning

confidence: 99%